Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group
E. Gonzalez-flores
British journal of cancer, 2009
View PDFchevron_right
Phase I and Pharmacokinetic Study of Oral Irinotecan Given Once Daily for 5 Days Every 3 Weeks in Combination With Capecitabine in Patients With Solid Tumors
Otto Soepenberg
Journal of Clinical Oncology, 2005
View PDFchevron_right
Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine
Louis Denis
Investigational New Drugs, 2012
View PDFchevron_right
Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial
Sebastian Stintzing
2011
View PDFchevron_right
A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer
Johan Nortier
Annals of Oncology, 2005
View PDFchevron_right
A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity
Razvan Popescu
Annals of Oncology, 2005
View PDFchevron_right
Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group
Axel Hinke
Annals of Oncology, 2013
View PDFchevron_right
A phase I clinical and pharmacokinetic study of capecitabine (Xeloda®) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours
Veronique Dieras, Jean-Yves Pierga
British Journal of Cancer
View PDFchevron_right
Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomised phase II study
Dong Shin
Annals of Oncology, 2010
View PDFchevron_right
Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma
Diego Cortinovis
Cancer, 2004
View PDFchevron_right
A Novel Combination of Cisplatin, Irinotecan, and Capecitabine in Patients with Advanced Cancer
Michael Jefford
Investigational New Drugs, 2000
View PDFchevron_right
Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer
Thomas Cartwright
Clinical colorectal cancer, 2005
View PDFchevron_right
First-Line Chemotherapy with Irinotecan plus Capecitabine for Advanced Colorectal Cancer
Dong Shin
Oncology, 2004
View PDFchevron_right
A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study
Masahiro Hirakawa
Cancer chemotherapy and pharmacology, 2017
View PDFchevron_right
Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer
Zhi Wang
Journal of Cancer Research and Clinical Oncology, 2010
View PDFchevron_right
Low Dose Capecitabine as Maintenance Therapy in Colorectal Cancer with Irresectable Metastasis
Ghada Meckawy
Research in Oncology
View PDFchevron_right
Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study
Miriam Vogelaar
Annals of Oncology, 2006
View PDFchevron_right
A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer
Masayoshi Kobune
Cancer Chemotherapy and Pharmacology, 2015
View PDFchevron_right
Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma
Hong Jun Lee, Ji-youn Han
Cancer, 2005
View PDFchevron_right
Capecitabine Plus Oxaliplatin and Bevacizumab, Followed by Maintenance Treatment With Capecitabine and Bevacizumab for Patients Aged > 75 Years With Metastatic Colorectal Cancer
Edoardo Francini
Clinical Colorectal Cancer, 2018
View PDFchevron_right
Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX
Fabienne Portales
Cancer Chemotherapy and Pharmacology, 2012
View PDFchevron_right
Long-Term Safety Data on S-1 Administered After Previous Intolerance to Capecitabine-Containing Systemic Treatment for Metastatic Colorectal Cancer
Marija Vidakovic
Clinical Colorectal Cancer, 2022
View PDFchevron_right
Capecitabine as third line therapy in patients with advanced colorectal cancer1
Pehr Lind
Acta Oncologica, 2005
View PDFchevron_right
A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer
Mitsukuni Suenaga
Drug design, development and therapy, 2015
View PDFchevron_right
Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer
Mustafa Benekli
Medical Oncology, 2007
View PDFchevron_right
Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda®)
Axel Grothey
European Journal of Oncology Nursing, 2004
View PDFchevron_right
Lower incidence of adverse events about capecitabine and oxaliplatin from the GOIM 2802 study: a commentary
Takeshi Nagasaka
Digestive Medicine Research
View PDFchevron_right
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015
C. Bokemeyer
Annals of Oncology, 2008
View PDFchevron_right
Capecitabine versus 5-fluorouracil in colorectal cancer: where are we now?
Stephen Williamson
Oncology Reviews, 2011
View PDFchevron_right
Irinotecan and Capecitabine (CAPIRI) Plus Bevacizumab in First-Line Treatment of Metastatic Colorectal Cancer
PAULA NATALI MARTINEZ FONSECA
Cancer and Clinical Oncology, 2012
View PDFchevron_right
Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: Final results of the Southern Italy Cooperative Oncology Group Trial 0108
vito lorusso
Cancer, 2005
View PDFchevron_right